US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lineage

45.62

+0.91002.04%

Post-market: 45.620.00000.00%19:04 EDT

Volume:944.51K

Turnover:42.93M

Market Cap:10.43B

PE:-14.36

High:45.80

Open:44.69

Low:44.53

Close:44.71

Loading ...

Overview Company News Filings

WONDER EXPANDS ICONIC BRAND WITH NEW LINE OF SWEET TREATS

VALUE LINE, INC. ANNOUNCES EARNINGS FOR FIRST NINE MONTHS OF FISCAL 2025

Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities

Lineage Cell Therapeutics price target lowered to $3 from $4 at B. Riley

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating

MT Newswires Live

Exclusive: Kaia Blockchain Debunks Soneium-LINE Partnership Claims, Vows Objections

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

MAISONS DU MONDE: ANNUAL RESULTS 2024 IN LINE WITH GUIDANCE: Positive free cash flow / Net Sales € 1.002 billion / Visible effects of Inspire Everyday expected in 2025, with a gradual return to growth

Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress

Lineage management to meet with Piper Sandler

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Lineage Is Maintained at Sector Outperform by Scotiabank

Lineage price target raised to $74 from $73 at Scotiabank

AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Lineage Is Maintained at Outperform by RBC Capital

Lineage, Inc. (LINE) Receives a Buy from Bank of America Securities

Lineage price target lowered to $74 from $81 at RBC Capital

RBC Cuts Price Target on Lineage to $74 From $81, Keeps Outperform Rating

MT Newswires Live

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LINE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LINE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LINE\",,,,,undefined,":{"symbol":"LINE","market":"US","secType":"STK","nameCN":"Lineage","latestPrice":45.62,"timestamp":1746820800000,"preClose":44.71,"halted":0,"volume":944507,"hourTrading":{"tag":"盘后","latestPrice":45.62,"preClose":45.62,"latestTime":"19:04 EDT","volume":8544,"amount":389776.68,"timestamp":1746831862869},"delay":0,"floatShares":70869467,"shares":228590171,"eps":-3.176192,"marketStatus":"Market Closed","change":0.91,"latestTime":"05-09 16:00:00 EDT","open":44.69,"high":45.8,"low":44.53,"amount":42927701.47395,"amplitude":0.028405,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.176192,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1721880000000,"exchange":"NASDAQ","adjPreClose":44.71,"dividendRate":0.031456,"preHourTrading":{"tag":"盘前","latestPrice":45.5,"preClose":44.71,"latestTime":"08:26 EDT","volume":254,"amount":11186.65784,"timestamp":1746793582767},"postHourTrading":{"tag":"盘后","latestPrice":45.62,"preClose":45.62,"latestTime":"19:04 EDT","volume":8544,"amount":389776.68,"timestamp":1746831862869},"volumeRatio":0.5844995377263563,"impliedVol":0.315,"impliedVolPercentile":0.1421},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LINE\",,,,,undefined,":{"symbol":"LINE","floatShares":70869467,"roa":"0.50%","roe":"-9.07%","lyrEps":-3.696335,"volumeRatio":0.5844995377263563,"shares":228590171,"dividePrice":1.435,"high":45.8,"amplitude":0.028405,"preClose":44.71,"low":44.53,"week52Low":42.05,"pbRate":"1.21","psRate":"1.97","week52High":89.85,"institutionHeld":0.1784,"latestPrice":45.62,"eps":-3.176192,"divideRate":0.031456,"volume":944507,"delay":0,"ttmEps":-3.176192,"open":44.69,"prevYearClose":58.57,"prevWeekClose":45.28,"prevMonthClose":48.23,"prevQuarterClose":58.63,"fiveDayClose":45.28,"twentyDayClose":52.22,"sixtyDayClose":56.55},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LINE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520521153","title":"WONDER EXPANDS ICONIC BRAND WITH NEW LINE OF SWEET TREATS","url":"https://stock-news.laohu8.com/highlight/detail?id=2520521153","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520521153?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:08","pubTimestamp":1742216880,"startTime":"0","endTime":"0","summary":"Over 100-Year-Old Brand Introduces a Deliciously Nostalgic Take on Classic Treats. THOMASVILLE, Ga., March 17, 2025 /PRNewswire/ -- Wonder, a household name for over a century, is making a sweet splash in the snack world with the launch of its first line of snack cakes. This exciting expansion marks a new chapter for the beloved brand, offering consumers a fresh take on classic indulgences with the same soft, fluffy texture and delicious taste they've come to expect from Wonder.Glazed Honey Buns– a soft, cinnamon-filled bun coated in a sweet glaze for the perfect balance of flavor and melt-in your mouth goodness. Powdered Mini Donuts– soft, bite-sized donuts covered in a sweet, powdered sugar coating for a deliciously light and classic treat. Crunch Donuts– soft, bite-sized donuts covered in a delicious crunch topping. Founded in 1921 in Indianapolis, Wonder Bread is named for the feeling that founder Elmer Cline experienced when watching a hot air balloon race. A century later, the br","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/wonder-expands-iconic-brand-line-130800180.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wonder-expands-iconic-brand-line-130800180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4224","BK4212","FLO","LINE"],"gpt_icon":0},{"id":"2519935359","title":"VALUE LINE, INC. ANNOUNCES EARNINGS FOR FIRST NINE MONTHS OF FISCAL 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2519935359","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519935359?lang=en_us&edition=fundamental","pubTime":"2025-03-15 05:27","pubTimestamp":1741987620,"startTime":"0","endTime":"0","summary":"NEW YORK, March  14, 2025  (GLOBE NEWSWIRE) --  Value Line, Inc., (NASDAQ: VALU) reported strong financial results: During the nine months ended January 31, 2025, the Company’s net income of $16,735,0","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/14/3043204/0/en/VALUE-LINE-INC-ANNOUNCES-EARNINGS-FOR-FIRST-NINE-MONTHS-OF-FISCAL-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INC","LINE","NINE","VALU","FOR"],"gpt_icon":0},{"id":"2519804244","title":"Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2519804244","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519804244?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:23","pubTimestamp":1741958580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LCTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 09:23 ET (13:23 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCTX","RILY","LENZ","LINE"],"gpt_icon":0},{"id":"2519806820","title":"Lineage Cell Therapeutics price target lowered to $3 from $4 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2519806820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519806820?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:20","pubTimestamp":1741954845,"startTime":"0","endTime":"0","summary":"B. Riley analyst Mayank Mamtani lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the sha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lineage-cell-therapeutics-price-target-lowered-to-3-from-4-at-b-riley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lineage-cell-therapeutics-price-target-lowered-to-3-from-4-at-b-riley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LINE","LENZ","RILY"],"gpt_icon":0},{"id":"2519042808","title":"B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2519042808","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519042808?lang=en_us&edition=fundamental","pubTime":"2025-03-14 19:55","pubTimestamp":1741953324,"startTime":"0","endTime":"0","summary":"Lineage Cell Therapeutics (LCTX) has an average rating of buy and mean price target of $4.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RILY","LENZ","LCTX","LINE"],"gpt_icon":0},{"id":"2519583303","title":"Exclusive: Kaia Blockchain Debunks Soneium-LINE Partnership Claims, Vows Objections","url":"https://stock-news.laohu8.com/highlight/detail?id=2519583303","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519583303?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:49","pubTimestamp":1741866563,"startTime":"0","endTime":"0","summary":"In a whirlwind of crypto speculation, Kaia blockchain, the ambitious layer-1 project born from the merger of Kakao’s Klaytn and LINE’s Finschia, has stepped forward to set the record straight. Recent whispers of a collaboration between Sony’s blockchain platform, Soneium, and messaging giant LINE have been firmly quashed by Kaia. For those deeply invested in the ever-evolving world of cryptocurrencies and blockchain developments, this clarification is crucial. Let’s dive into the heart of this unfolding story and understand what it truly means for the future of these platforms.Kaia Blockchain’s Swift Response to Partnership Rumors. The crypto sphere is no stranger to rumors and speculation, and the supposed partnership between Soneium and LINE was quickly gaining traction. However, Kaia blockchain acted decisively to address these claims head-on. Through an official announcement on their Discord channel, Kaia made it unequivocally clear: there is no partnership between Soneium and LINE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67d2c6445e488a7a572ddc7f/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["TON.USD.CC","BK4224","KAIA.USD.HKCC","APT.USD.HKCC","TON.USD.HKCC","APT.USD.CC","LINE"],"gpt_icon":0},{"id":"2518698037","title":"Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518698037","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518698037?lang=en_us&edition=fundamental","pubTime":"2025-03-12 14:01","pubTimestamp":1741759308,"startTime":"0","endTime":"0","summary":"Lineage Cell Therapeutics, Inc. (LCTX) has disclosed a new risk, in the Economy & Political Environment category. Lineage Cell Therapeutics, Inc. f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lineage-cell-therapeutics-faces-uncertainty-amid-new-u-s-administrations-policies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lineage-cell-therapeutics-faces-uncertainty-amid-new-u-s-administrations-policies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LINE","BK4139","LCTX","LENZ","BK4224"],"gpt_icon":0},{"id":"2518712410","title":"Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2518712410","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518712410?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:15","pubTimestamp":1741691700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LCTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 07:15 ET (11:15 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCTX","LENZ","LINE"],"gpt_icon":0},{"id":"2518768733","title":"MAISONS DU MONDE: ANNUAL RESULTS 2024 IN LINE WITH GUIDANCE: Positive free cash flow / Net Sales € 1.002 billion / Visible effects of Inspire Everyday expected in 2025, with a gradual return to growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2518768733","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518768733?lang=en_us&edition=fundamental","pubTime":"2025-03-11 14:00","pubTimestamp":1741672800,"startTime":"0","endTime":"0","summary":"Visible effects of Inspire Everyday expected in 2025, with a gradual return to growth. Generated free cash flow  of 15m driven by strict control of working capital requirements  and by 45m in cost savings, despite lower turnover . A store network of 338 stores, of which 14 managed by affiliates. 63 revamped stores, including new concept in 2 shopping centers, with capex/sales below 2.5%. Launched loyalty program in France in October 2024 and rebalanced media mix with a refocus on the Brand. Improved customer experience in France: NPS increased by 4 points. Opening of new stores, particularly through affiliate and franchise partners. Continued efforts on customer events to further promote the Brand. Category extensions, notably including bathroom, outdoor lighting and pet accessories. Continued store renovations with a focus on shopping centers: targeting a total of 100 revamped stores by 2025 year-end, while maintaining the capex/sales ratio around 2.5%. Group sales for the year 2024 a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maisons-du-monde-annual-results-060000607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LINE","MDOUF"],"gpt_icon":0},{"id":"2518805759","title":"Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2518805759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518805759?lang=en_us&edition=fundamental","pubTime":"2025-03-11 11:54","pubTimestamp":1741665261,"startTime":"0","endTime":"0","summary":"Lineage Cell Therapeutics, Inc. ( ($LCTX) ) has released its Q4 earnings. Here is a breakdown of the information Lineage Cell Therapeutics, Inc. pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lineage-cell-therapeutics-2024-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lineage-cell-therapeutics-2024-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","LINE","LU2065732104.USD","PRGS","BK4224","BK4097","BK4139"],"gpt_icon":0},{"id":"2518992785","title":"Lineage management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2518992785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518992785?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:50","pubTimestamp":1741639842,"startTime":"0","endTime":"0","summary":"Meeting to be held in Los Angeles on March 11 and in San Francisco on March 12 hosted by Piper Sandler. Published first on TheFly – the ultimate so...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lineage-management-to-meet-with-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lineage-management-to-meet-with-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4224","LINE"],"gpt_icon":0},{"id":"2518178313","title":"Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2518178313","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518178313?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":"Positive 24 Month Visual Acuity Data with OpRegen in Geographic Atrophy Patients Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit. Signed Services Agreement with Genentech to Further Support Ongoing OpRegen Development. Completed Two Financings Totaling $44 Million in Gross Proceeds; Potential for an Additional $36 Million in Gross Proceeds Upon Full Cash Exercise of Clinical Milestone-linked Warrants. Initiated OPC1 Device Delivery Study in Patients with Subacute and Chronic Spinal Cord Injury. Hosted Annual Spinal Cord Injury Symposium with Christopher & Dana Reeve Foundation. Presented ReSonance  Preclinical Results at 59th Annual Inner Ear Biology Workshop. CARLSBAD, Calif., March 10, 2025----Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lineage-cell-therapeutics-reports-fourth-200500174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1064131342.USD","LU1880398554.USD","LU2054465674.USD","LU2250418816.HKD","LENZ","LU0823421333.USD","LU2098885051.SGD","LU2458330169.SGD","LU0889565833.HKD","BK4588","BK4529","BK4543","LINE","BK4566","LU1989764664.SGD","LU0719512351.SGD","LU0823434583.USD","BK4141","LU1951198990.SGD","LU1951200564.SGD","BK4534","LU0390134368.USD","LU1303367103.USD","LU2458330243.SGD","BK4573","IE00BMPRXN33.USD","LU0823421416.USD","LU2264538146.SGD","BK4605","LU1242518857.USD","BK4139","BK4585","LU1803068979.SGD","LU0081259029.USD","BK4614","LU0082616367.USD","LU0823434740.USD","LU0127658192.USD","BK4554","IE0004445239.USD","LCTX","LU0979878070.USD","LU2360106780.USD","LU0198837287.USD","LU0642271901.SGD","BK4224","IE00B5949003.HKD","LU1242518931.SGD","IE0009356076.USD"],"gpt_icon":1},{"id":"2518065332","title":"Lineage Is Maintained at Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2518065332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518065332?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:09","pubTimestamp":1741630140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LINE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 14:09 ET (18:09 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LINE"],"gpt_icon":0},{"id":"2518927834","title":"Lineage price target raised to $74 from $73 at Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2518927834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518927834?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:16","pubTimestamp":1741616160,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Greg McGinniss raised the firm’s price target on Lineage (LINE) to $74 from $73 and keeps an Outperform rating on the shares. Wh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lineage-price-target-raised-to-74-from-73-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lineage-price-target-raised-to-74-from-73-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LINE"],"gpt_icon":0},{"id":"2517987443","title":"AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","url":"https://stock-news.laohu8.com/highlight/detail?id=2517987443","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517987443?lang=en_us&edition=fundamental","pubTime":"2025-03-08 19:00","pubTimestamp":1741431600,"startTime":"0","endTime":"0","summary":"Ongoing Studies are Evaluating Long-Term Maintenance and Durability. THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ --Amgen  and Kyowa Kirin Co., Ltd.  today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis .The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose strengths versus placebo. IGNITE was a 24-week, randomized, placebo-controlled, double-blind studyto assess the efficacy, safety and tolerability of rocatinlimab monotherapy every 4 weeks in 769 adults with moderate to severe AD, including patients previously treated with a biologic or systemic Janus kinase  inhibitor medication.\"Many patients with moderate to severe atopic dermatitis struggle with chronic, life-d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-kyowa-kirin-top-line-110000762.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-kyowa-kirin-top-line-110000762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","TCS","LU0058720904.USD","IE00B4R5TH58.HKD","LU0868494617.USD","LU0109394709.USD","LU0289739699.SGD","BK4588","LU1983299246.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0320765992.SGD","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","LU1571399168.USD","KYKOY","BK4581","IE00BFTCPJ56.SGD","LU2242646821.SGD","BK4534","SG9999001440.SGD","AMGN","BK4224","BK4200","LU1061106388.HKD","BK4566","BK4599","LU0889565916.HKD","LU2242652126.USD","BK4139","LINE","BK4233","BK4533","LU0122379950.USD","TCI","BK4205","IE0009355771.USD","LU2112291526.USD","KYKOF"],"gpt_icon":0},{"id":"2517169844","title":"Lineage Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2517169844","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517169844?lang=en_us&edition=fundamental","pubTime":"2025-03-06 23:01","pubTimestamp":1741273260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LINE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 10:01 ET (15:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LINE"],"gpt_icon":0},{"id":"2517165668","title":"Lineage, Inc. (LINE) Receives a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2517165668","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517165668?lang=en_us&edition=fundamental","pubTime":"2025-03-06 22:25","pubTimestamp":1741271159,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Joshua Dennerlein from Bank of America Securities reiterated a Buy rating on Lineage, Inc. (LINE – Research Report)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lineage-inc-line-receives-a-buy-from-bank-of-america-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lineage-inc-line-receives-a-buy-from-bank-of-america-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BBT3K403.USD","LU2129689514.USD","LU0648000940.SGD","IE00BKVL7J92.USD","LU1668664300.SGD","LU1074936037.SGD","LU0648001328.SGD","LU0980610538.SGD","LU1718418525.SGD","LU0320765646.SGD","LU0971096721.USD","LU1496350171.SGD","LU0321505439.SGD","BK4534","LU0170899867.USD","LU1280957306.USD","BK4553","LU0321505868.SGD","LU0098860793.USD","LU0208291251.USD","LU2133065610.SGD","IE00BZ1G4Q59.USD","LU1883839398.USD","LU2129689605.HKD","LU0683600562.USD","LU0130518102.USD","LU0256863811.USD","BK4504","IE00B19Z3B42.SGD","BK4559","LU1363072403.SGD","LU1162221912.USD","LU0310800965.SGD","LU0868494617.USD","LU0130103400.USD","LU1496350502.SGD","LU1506573853.SGD","BK4585","LU0314106906.USD","LU0417517546.SGD","LU1894683348.USD","BK4581","LU1267930227.SGD","LU0130102774.USD","BAC","IE00BFXG1179.USD","LU0234572021.USD","BK4207","LINE","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2517688521","title":"Lineage price target lowered to $74 from $81 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2517688521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517688521?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:51","pubTimestamp":1741269088,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Michael Carroll lowered the firm’s price target on Lineage (LINE) to $74 from $81 and keeps an Outperform rating on the shares....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lineage-price-target-lowered-to-74-from-81-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lineage-price-target-lowered-to-74-from-81-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LINE"],"gpt_icon":0},{"id":"2517515535","title":"RBC Cuts Price Target on Lineage to $74 From $81, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517515535","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517515535?lang=en_us&edition=fundamental","pubTime":"2025-03-06 19:34","pubTimestamp":1741260898,"startTime":"0","endTime":"0","summary":"Lineage (LINE) has an average rating of overweight and mean price target of $70.69, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LINE"],"gpt_icon":0},{"id":"2517148859","title":"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517148859","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517148859?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:00","pubTimestamp":1741179600,"startTime":"0","endTime":"0","summary":"CARLSBAD, Calif., March 05, 2025----Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lineage-cell-therapeutics-report-fourth-130000477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4224","LINE","LENZ","LCTX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":188,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LINE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-30","symbol":"LINE","fiscalQuarterEnding":"2025/03","expectedEps":0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1745985600000,"reportTimeType":"pre","actualEps":0.86},{"date":"2025-03-31","symbol":"LINE","amount":0.5275,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"Lineage","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-21","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-21"},{"market":"US","date":"2025-02-26","symbol":"LINE","fiscalQuarterEnding":"2024/12","expectedEps":0.68,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740546000000,"reportTimeType":"pre","actualEps":0.83},{"date":"2024-12-31","symbol":"LINE","amount":0.5275,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-31","defaultRemindTime":1735655400000,"name":"Lineage","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-21","payableDate":"2024-12-31","currency":"USD","dateTimestamp":1735621200000,"payDate":"2025-01-21"},{"market":"US","date":"2024-11-06","symbol":"LINE","fiscalQuarterEnding":"2024/09","expectedEps":0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"pre","actualEps":0.9}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LINE\",market:\"US\",,,undefined,":[{"executeDate":"2024-09-30","recordDate":"2024-09-30","paymentDate":"2024-10-21","value":0.38,"currency":"USD"},{"executeDate":"2024-12-31","recordDate":"2024-12-31","paymentDate":"2025-01-21","value":0.5275,"currency":"USD"},{"executeDate":"2025-03-31","recordDate":"2025-03-31","paymentDate":"2025-04-21","value":0.5275,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LINE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0556,"buy":0.4444,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4444,"analysts":18,"updateTime":1746590400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LINE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LINE","date":"2025-05-08","current":-16.096558,"percent":0.994737,"low":-150.084638,"twenty":-90.639401,"median":-21.446806,"eighty":-19.908189,"high":-16.037945,"avg":-49.715972,"sd":42.136085,"marketCap":10044252113},"quantilePoints":[{"date":"2024-08-02","current":-146.000818,"twenty":-146.000818,"median":-146.000818,"eighty":-146.000818,"marketCap":19680910257},{"date":"2024-08-09","current":-150.084638,"twenty":-146.017763,"median":-145.856783,"eighty":-145.221334,"marketCap":20231409255},{"date":"2024-08-16","current":-142.88288,"twenty":-146.017763,"median":-145.492459,"eighty":-142.88288,"marketCap":19260612266},{"date":"2024-08-23","current":-142.59261,"twenty":-146.509177,"median":-145.602603,"eighty":-142.59261,"marketCap":19221483852},{"date":"2024-08-30","current":-95.803712,"twenty":-146.271943,"median":-143.713201,"eighty":-98.730155,"marketCap":19007456432},{"date":"2024-09-06","current":-95.402043,"twenty":-146.068599,"median":-142.59261,"eighty":-96.597868,"marketCap":18927765371},{"date":"2024-09-13","current":-94.621658,"twenty":-146.004207,"median":-142.327922,"eighty":-95.080709,"marketCap":18772937025},{"date":"2024-09-20","current":-94.254418,"twenty":-145.770362,"median":-98.489154,"eighty":-94.64002,"marketCap":18700076626},{"date":"2024-09-27","current":-89.824587,"twenty":-145.536517,"median":-96.48081,"eighty":-93.930788,"marketCap":17821198071},{"date":"2024-10-04","current":-88.080197,"twenty":-145.275559,"median":-95.539758,"eighty":-92.831364,"marketCap":17475111178},{"date":"2024-10-11","current":-84.912753,"twenty":-144.014828,"median":-95.063494,"eighty":-89.930169,"marketCap":16846690242},{"date":"2024-10-18","current":-87.712958,"twenty":-143.048944,"median":-94.644611,"eighty":-88.075607,"marketCap":17402250780},{"date":"2024-10-25","current":-89.158965,"twenty":-142.650664,"median":-94.409347,"eighty":-88.190369,"marketCap":17689138599},{"date":"2024-10-31","current":-86.301379,"twenty":-142.563428,"median":-93.892916,"eighty":-87.898873,"marketCap":17122193624},{"date":"2024-11-08","current":-24.107959,"twenty":-142.432135,"median":-92.969079,"eighty":-87.45589,"marketCap":15535169004},{"date":"2024-11-15","current":-22.358645,"twenty":-142.321991,"median":-92.056717,"eighty":-86.491885,"marketCap":14407910854},{"date":"2024-11-22","current":-22.291364,"twenty":-116.1574,"median":-90.604972,"eighty":-85.11244,"marketCap":14364554771},{"date":"2024-11-29","current":-22.457796,"twenty":-98.633755,"median":-89.84754,"eighty":-83.062782,"marketCap":14471804028},{"date":"2024-12-06","current":-22.273658,"twenty":-98.328486,"median":-89.399966,"eighty":-23.717728,"marketCap":14353145276},{"date":"2024-12-13","current":-22.082438,"twenty":-97.522854,"median":-88.367104,"eighty":-22.894771,"marketCap":14229922725},{"date":"2024-12-20","current":-20.148985,"twenty":-96.51983,"median":-88.068721,"eighty":-22.516579,"marketCap":12984005822},{"date":"2024-12-27","current":-20.846586,"twenty":-96.189314,"median":-87.867887,"eighty":-22.462754,"marketCap":13433539942},{"date":"2025-01-03","current":-20.665989,"twenty":-95.803712,"median":-87.603934,"eighty":-22.358645,"marketCap":13317163089},{"date":"2025-01-10","current":-19.996717,"twenty":-95.592549,"median":-87.449004,"eighty":-22.235414,"marketCap":12885884161},{"date":"2025-01-17","current":-20.329582,"twenty":-95.429586,"median":-87.127669,"eighty":-22.065441,"marketCap":13100382675},{"date":"2025-01-24","current":-21.186534,"twenty":-95.216128,"median":-86.381713,"eighty":-21.592346,"marketCap":13652602255},{"date":"2025-01-31","current":-21.229027,"twenty":-95.057756,"median":-85.698876,"eighty":-21.234693,"marketCap":13679985044},{"date":"2025-02-07","current":-20.619954,"twenty":-94.91086,"median":-83.983177,"eighty":-21.199282,"marketCap":13287498401},{"date":"2025-02-14","current":-19.908189,"twenty":-94.718059,"median":-53.523399,"eighty":-20.89262,"marketCap":12828836683},{"date":"2025-02-21","current":-19.369938,"twenty":-94.63543,"median":-23.897456,"eighty":-20.823215,"marketCap":12481988022},{"date":"2025-02-28","current":-20.503397,"twenty":-94.598706,"median":-23.236843,"eighty":-20.740352,"marketCap":13614255869},{"date":"2025-03-07","current":-20.963916,"twenty":-94.440333,"median":-22.902207,"eighty":-20.736811,"marketCap":13920040363},{"date":"2025-03-14","current":-19.513626,"twenty":-94.135065,"median":-22.613606,"eighty":-20.682059,"marketCap":12957047406},{"date":"2025-03-21","current":-20.723347,"twenty":-93.90554,"median":-22.503831,"eighty":-20.657101,"marketCap":13760302194},{"date":"2025-03-28","current":-20.579005,"twenty":-93.783892,"median":-22.457796,"eighty":-20.605323,"marketCap":13664459294},{"date":"2025-04-04","current":-19.386467,"twenty":-93.416653,"median":-22.388745,"eighty":-20.521213,"marketCap":12872614375},{"date":"2025-04-11","current":-17.946487,"twenty":-92.941536,"median":-22.273658,"eighty":-20.34233,"marketCap":11916467340},{"date":"2025-04-17","current":-18.86237,"twenty":-92.831364,"median":-22.224082,"eighty":-20.27245,"marketCap":12524613365},{"date":"2025-04-25","current":-19.376157,"twenty":-92.356247,"median":-22.119619,"eighty":-20.124586,"marketCap":12865768453},{"date":"2025-05-02","current":-17.298122,"twenty":-91.37388,"median":-21.962039,"eighty":-20.00357,"marketCap":10794027874},{"date":"2025-05-08","current":-16.096558,"twenty":-90.639401,"median":-21.446806,"eighty":-19.908189,"marketCap":10044252113}],"updateTime":1746856602108}}}